key: cord-0756367-h0s6iq78
authors: Sapkal, Gajanan; Yadav, Pragya D; Ella, Raches; Abraham, Priya; Patil, Deepak Y; Gupta, Nivedita; Panda, Samiran; Mohan, V Krishna; Bhargava, Balram
title: Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of inactivated COVID-19 vaccine Covaxin
date: 2021-05-17
journal: J Travel Med
DOI: 10.1093/jtm/taab077
sha: 7fbca3c4febd6ecbbb1ccb48f14c501f93c7c2ea
doc_id: 756367
cord_uid: h0s6iq78

Our study has shown 1.09 and 1.92 fold reductions in the neutralizing titer with sera of individuals with natural infection and Covaxin vaccine recipients against B.1.1.28.2 variant.

The geometric mean titer (GMT) of an IgG titer for S1-RBD and N protein ELISA (In house assays developed with prototype Wuhan-Hu-1 strain) was observed to be 794.8 and 4627

respectively for the SARS-CoV-2 recovered individuals. Covaxin recipients showed a GMT IgG titer of 2250 with S1-RBD and 3099 with the N protein compared; the former being significantly high compared to natural infection ( Figure 1A ). The geometric mean titer (GMT) of the lineage. Wilcoxon matched-pairs signed-rank test was used to compare the significance. A significant reduction was observed in the samples of the vaccines, whereas a non-significant change was observed in the cases with natural Infection.

The study is approved by the Institutional Biosafety Committee and Institutional Human Ethics

Committee of ICMR-NIV, Pune, India

PDY, RE and PA contributed to study design, data collection, data analysis, interpretation and writing and critical review. GS and DYP contributed to data collection, interpretation, writing and critical review. NG, SP, VKM and BB contributed to critical review and finalization of the paper.

Authors do not have conflict of interest. 

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1.7): an exploratory analysis of a randomised controlled trial

Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B. 1.351 variant in South Africa

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y. V2 (B. 1.351)

Isolation and characterization of the new SARS-CoV-2 variant in travellers from the United Kingdom to India: VUI-202012/01 of the B.1.1.7 lineage

Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B 1.1.7 variant of SARS-CoV-2

Neutralization by Antibodies Elicited after Natural Infection and Vaccination

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine

We thank the scientific staff of ICMR-NIV, Pune Dr. Anita Shte, Dr. Rima Sahay, Dr. Gururaj Deshpande, Dr. Dimpal Nyayanit and Dr. Abhinendra Kumar for providing excellent support.Authors gratefully acknowledge the staff of ICMR-NIV, Pune including Mr. Prasad Sarkale, Ms.